| Issue Size | ₹1,300 CrRights Issue Ceiling |
|---|---|
| Market Cap | ₹14,807 CrMid-cap Pharma |
| P/E TTM | 12.94xSector PE 49.62x |
| RSI | 31.11Near Oversold |
| Deal value | ₹1,300 Cr |
| Share of market cap | 8.8% |
Key highlights
- Rights issue approved for a total amount not exceeding ₹1,300 crore
- Equity shares to be issued at a face value of ₹2 each to eligible shareholders
- Three-member Fund-Raising Committee constituted to oversee the execution
- Demerger scheme with Natco Crop Health Sciences to be revised post-fundraise
- Company TTM revenue stands at ₹3,484.6 crore with a P/E ratio of 12.94x
Details of the Proposed Rights Issue
The board of directors of Natco Pharma has greenlit the issuance of fully paid-up equity shares with a face value of ₹2 each through a rights issue mechanism. The total proceeds from this issuance are capped at ₹1,300 crore. While the specific entitlement ratio, issue price, and record date are yet to be determined, the company has established a dedicated Fund-Raising Committee to manage the process.
This committee includes Sri V.C. Nannapaneni as Chairman, alongside Sri Rajeev Nannapaneni and Sri P.S.R.K. Prasad.
The initiative remains subject to necessary regulatory approvals under SEBI ICDR Regulations.
Impact on Demerger and Capital Structure
- The proposed fundraise will lead to changes in the company's capital structure and shareholding pattern.
- Management has decided to modify the existing Scheme of Arrangement with Natco Crop Health Sciences Limited.
- Revisions will be made post-rights issue to ensure the share swap ratio remains consistent with previous proposals.
- The company has already received observation letters from stock exchanges but has not yet filed the scheme with the NCLT.
- Updated filings for the demerger will be submitted to the exchanges once the rights issue is completed.
Business and Financial Context
Natco Pharma operates primarily in the research, development, and manufacturing of complex generics and specialty pharmaceuticals, with a significant presence in oncology and gastroenterology. The company reported TTM operating revenue of ₹3,484.6 crore and a net profit of ₹1,144.3 crore. With a current price-to-earnings (P/E) ratio of 12.94x compared to the sector average of 49.62x, the company maintains a moderate valuation profile.
The strategic shift to demerge its crop health division reflects a focus on streamlining its core pharmaceutical operations while allowing the agritech business to scale independently.
Market Performance and Ownership
- Promoter holding remains stable at 49.42% as of the latest reporting quarter.
- Foreign Institutional Investors (FII) hold a 16.99% stake, showing a slight QoQ decrease of 0.38%.
- The stock is currently trading below its 200-day SMA of 945.69 and 50-day SMA of 911.61.
- Annual cash flow from operating activities was reported at ₹1,768.3 crore for the last fiscal year.
- Short-term momentum indicators show a Day RSI of 31.11, suggesting the stock is approaching the oversold zone.
| Share price | ₹826.7 |
|---|---|
| Market capitalisation | ₹14,807.02 Cr |
| Revenue (annual) | ₹4,078.30 Cr |
| Net profit (annual) | ₹1,418.50 Cr |
| Revenue (latest quarter) | ₹735.20 Cr-0.53% vs previous quarter |
| Net profit (latest quarter) | ₹206.50 Cr-22.92% vs previous quarter |
| P/E (TTM) | 12.94×Sector 49.62× |
| Promoter holding | 49.42%0.00% QoQ |
| FII holding | 16.99%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Natco Pharma Ltd announcing the board's approval for a rights issue up to ₹1,300 crore and updates on the demerger scheme. Market figures from a third-party data provider.
